Last updated on March 2019

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Brief description of study

This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies.

-The names of the study drugs involved in this study are:

  • Nivolumab
  • Ipilimumab

Detailed Study Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the combination of drugs works in treating a specific disease. "Investigational" means that the drugs are being studied.

The FDA (the U.S. Food and Drug Administration) has not approved nivolumab in combination with ipilimumab for this specific disease but the combination is approved for use in melanoma patients.

In this research study, the investigators are...

  • Investigating the response of the participant's cancer to treatment with nivolumab plus ipilimumab,
  • Assessing the safety of treatment with nivolumab and ipilimumab and
  • Evaluating response and resistance to treatment by looking at the participant's tumor tissue and blood for markers to predict response and resistance to therapy.

Clinical Study Identifier: NCT03333616

Contact Investigators or Research Sites near you

Start Over

Glenn Bubley, MD

Beth Israel Deaconess Medical Center
Boston, MA United States
  Connect »

Bradley A McGregor, MD

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

Matthew Campbell, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Rana McKay, MD

University of California, San Diego Moores Cancer Center
La Jolla, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.